European Regulatory Experiences and Expectations of HCP Analysis and Control
|
|
- Louisa Douglas
- 6 years ago
- Views:
Transcription
1 HCP Strategy Forum, Washington DC, January 26, European Regulatory Experiences and Expectations of HCP Analysis and Control Blood Products: Dr. Erika Friedl, PEI (DE) Discalimer: The views presented here are my own and do not necessarily reflect the views of the Paul-Ehrlich-Institute or any other European regulatory body January
2 Recombinant Blood Products (rfviii, rfix, ) Regulatory framework Marketing authorization Goal: ensure production of safe biotechnology products with regard to the risk of residual process-related impurities: HCPs, host cell DNA General guidelines/monographs Guideline 3AB1A - Production and quality control of medicinal products derived by recombinant DNA technology (1995) EP monograph 0784 Products of Recombinant DNA technology (01/2008) 2
3 Recombinant Blood Products (rfviii, rfix,...) Specifications ICH Q6B (CPMP/ICH/365/96) NfG on specifications: Test procedures and acceptance criteria for biotechnological/ biological products (1999) Specification versus validation approach CPMP/BWP/382/97 - Position statement on DNA and Host Cell Protein impurities, routine testing versus validation studies (1997) 3
4 Recombinant Blood Products (rfviii, rfix, ) Comparability exercise after process changes ICH Q5E (CPMP/ICH/5721/03) NfG on biotechnological/biological products subject to changes in their manufacturing process (2005) Biosimilarity exercise EMA/CHMP/BWP/247713/ Similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (rev. 1, effective ) 4
5 Recombinant Blood Products (rfviii, rfix, ) Clinical Drug Development Phase I-III EMEA/CHMP/BWP/534898/08 - Requirements for quality documentation concerning biological investigational medicinal products in clinical trials (2012) EP monograph regarding Immunological Assays/Validation EP (20701) Immunochemical methods (01/2008) 5
6 European Pharmacopoeia HCP assay for HCP assays currently no specific EP monograph available suitable HCP assays are required due to the heterogeneous nature of HCPs in medicinal products, dependent on the specific manufacturing process EDQM (European Directorate for the Quality of Medicines & HealthCare) has recently initiated a working party to draft a monograph on general considerations/recommendations on HCP testing and characterization Publication in Pharmeuropa in April 2015 Talk by Kowid Ho 6
7 Requirements for HCP testing/characetrization Summary of guideline requirements: a sensitive assay (e.g. immunoassay) capable of detecting a wide range of host cell protein impurities should be used test system should be validated the active substance is tested for process-related impurities including HCPs control of HCPs are typically part of the drug substance specification - the upper impurity level should be defined, limit decision is made on case by case basis 7
8 Requirements for HCP testing Specification setting for HCPs (EMA Guideline ICH Q6B) specifications are linked to the manufacturing process specifications should be based on lots used in pre-clinical and clinical studies prerequisite: material used in pre-clinical and clinical studies is representative of the commercial process linked to analytical procedures confirm that data generated during development correlate with data generated at the time of filing the marketing authorization 8
9 Requirements for HCP testing Upper safety limits for HCP impurities are not defined CPMP/BWP/382/97 - Position statement on DNA and host cell protein impurities, routine testing versus validation studies (1997) not possible to set a common limit for different products qualitative and quantitative HCP pattern depends on the individual manufacturing process Regulatory requirement: Reduction of host cell impurities to an acceptable level (as much as possible) in a consistent and reproducible manner using a well-controlled manufacturing process 9
10 Case studies Blood Products General apects for HCP testing: No examples for platform production / platform HCP assays HCP assay development as in-house and as commercial assay Validation approach not used HCP testing performed at the drug substance level HCP clearance studies performed across different manufacturing steps Drug substance specification limits for HCPs are usually in discussion should reflect the range tested in clinical studies and the routine process Successful marketing authorization application: mostly with in-house process-specific HCP assays 10
11 Case study 1 - Drug substance, 1/3 CHO HCP testing (sandwich ELISA) implemented as part of the Drug Substance Specification Development of Host Cell Protein assay (CHO) explained same in-house assay used for all stages of development Analytical procedure, reagents, standards, antibodies described in detail CHO reference material (pooled CHO antigens from supernatant of fermentation process) Preparation of different polyclonal antibodies using antigens obtained by different culture/harvesting methods multispecific antibody 11
12 Case study 1 - Drug substance, 2/3 Pooling of polyclonal antibodies performed to improve HCP coverage (tested/selected on ELISA basis) Same polyclonal antibody used for capture and detection Validation of analytical in-house test provided (ICH Q2 (R1)) HCP coverage shown by different test methods: 1D-SDS PAGE Coomassie, Silver stain and Western blot Estimated HCP coverage: ~ 80 % All batches tested for HCP levels clinical, validation and commercial batches HCP levels around X000 ppm observed 12
13 Case study 1 - Drug substance, 3/3 HCP levels around X000 ppm observed initially proposed limit considered too high when compared to the HCP batch results for routine and clinical batches (after improved manufacturing process) about X0 batches were tested - only few batches with high ppm values found Tightening of HCP specification limit according to the DS batch analysis data (for routine and clinical batches) was requested HCP specification limit was reduced to X000/2 ppm represents improved routine manufacturing process covered by clinical trials 13
14 Case study 2 - Drug substance, 1/4 Marketing authorization application not successful CHO HCP testing performed using a commercial ELISA assay (same polyclonal antibody for capture and detection) Problem low sensitivity for HCPs (different commercial assays used during clinical development until MAA) Estimated coverage (generic assay, test kit): ~ 60 to 80 % ELISA, 2D electrophoresis (silver stain) and Western blot During the MAA procedure, a new process-specific HCP ELISA was developed with up to 30 to 50-fold higher sensitivity thus much higher HCP levels were observed, validation pending 14
15 Case study 2 - Drug substance, 2/4 Clinical studies: antibodies against CHO HCPs observed in patients (up to 1/4 of enrolled patients) Anti-CHO-AB not associated with any clinical relevant events (no safety issues or other abnormal lab results) Immunogenicity risk assessment no change in risk profile accord. to company Baseline screening for some patients missing Different reactivity for different patient sample batches observed potential explanation? (5% to 25 %) 15
16 Case study 2 - Drug substance, 3/4 Clinical trial amendment and revision of risk management plan was necessary Additional testing of patients was proposed Attempts were made to identify the HCP antigen(s) to which the patient antibodies are directed (LC-MS/MS, LC-MRM) Preventive measure: introduction of a polishing step to reduce HCPs change in manufacturing process during MAA Problem for company: additional data requirement MAA time lines 16
17 Case study 2 - Drug substance, 4/4 Problems and required steps: Reduction of high HCP levels (and other impurities) in the drug substance by additional polishing step Due to change of the manufacturing process - additional clinical data with the impurity-reduced material were required could not be performed within MAA time lines 17
18 Conclusions for HCP testing/characetrization Summary of requirements: a sensitive assay (e.g. immunoassay, ) capable of detecting a wide range of HCPs should be used, preferably process-specific development of the assay, the reagents and the standards should be described validated test system should be used HCP testing should be implemented as part of the drug substance specification upper impurity level should be defined - representative of the routine process and the clinical studies (case by case) identification of main impurities (?), risk assessment 18
New General Chapter on Host Cell Protein Assays (2.6.34)
European Pharmacopoeia Training Session on Biologicals 7-8 February 2017, Strasbourg New General Chapter on Host Cell Protein Assays (2.6.34) Gwenael Cirefice Scientific Officer, European Pharmacopeia
More informationAffigenix Biosolutions Private Ltd, 265/ 1F, KSSIDC Industrial Area Bangalore, Karnataka,India
Host Cell Protein & Other Impurity Clearance Assays for Biosimilar Development Omics Biowaivers, Biologics & Biosimilars- Oct 29, 2014 Affigenix Biosolutions Private Ltd, 265/ 1F, KSSIDC Industrial Area
More informationRisk Assessments for Host Cell Protein Control Strategies: CDER Experiences
Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences Laurie Graham FDA/CDER Office of Pharmaceutical Quality (OPQ) Office of Policy for Pharmaceutical Quality (OPPQ) 1 Disclaimer
More informationPh. Eur. monographs and biosimilars
Ph. Eur. monographs and biosimilars Emmanuelle Charton, Ph. D. European Pharmacopoeia Department European Directorate for the Quality of Medicines & HealthCare 1 Place of the Ph. Eur. within the EU regulatory
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationThe Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives
The Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products CDER/FDA CASSS, Applications of
More informationPrioritizing and Managing Key CMC Elements
Prioritizing and Managing Key CMC Elements Using 21 st Century Principles during Early Development Laurie Graham Product Quality/CMC Reviewer FDA/CDER/OPS/OBP Division of Monoclonal Antibodies 1 Disclaimer
More informationHOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT
HOST CELL PROTEIN & BIOPROCESSING REAGENT DEVELOPMENT INTRODUCTION Biopharmaceuticals require products to be free of residual host cell protein (HCP) contaminants from the bioprocessing workflow. To evaluate
More informationPaving the way for Non-Clinical Bioanalytical Partnerships Louise Angell
Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell Content Overview of non-clinical immunogenicity testing for biologics Regulatory guidance Bioanalytical considerations Risk based
More informationFDA HCP assays are current the weakest analytical link in the total control strategy for biotech products
FDA HCP assays are current the weakest analytical link in the total control strategy for biotech products What are the best ways to prepare antigen/antibody reagents with highest HCP coverage? There was
More information1225 Eye Street NW, Ste. 400 Washington, DC 20005
1225 Eye Street NW, Ste. 400 Washington, DC 20005 30 June 2005 EMEA Biologics Working Party Secretariat Attention: Linda Olsson European Medicines Agency 7 Westferry Circus Canary Wharf London E14 4HB
More informationExamples of regulatory expectations for analytical characterization and testing
Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?
More informationGuideline on process validation for the manufacture of biotechnology-derived active substances and data to be provided in the regulatory submission
1 2 3 25 April 2014 EMA/CHMP/BWP/187338/2014 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on process validation for the manufacture of biotechnology-derived active substances
More informationGuide. recombinant DNA proteins. for the elaboration of monographs on synthetic peptides and. European Pharmacopoeia
Guide for the elaboration of monographs on synthetic peptides and recombinant DNA proteins European Pharmacopoeia European Directorate for the Quality of Medicines & HealthCare Edition Council of Europe,
More informationGuideline on Similar Biological Medicinal Products
1 2 3 22 May 2013 CHMP/437/04 Rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Draft 7 Draft agreed by Biosimilar Medicinal Products Working Party and Biologics Working Party March 2013
More informationGuideline for the quality, safety and efficacy of follow-on biological medicinal products
Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a
More informationLondon, 11 October 2006 Doc. Ref. EMEA/CHMP/BWP/271475/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency 1 2 London, 11 October 2006 Doc. Ref. 3 4 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) 5 DRAFT 6 7 GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY MEDICINAL
More informationRegulatory Perspective on Analytical Method Validation During Product Development
Regulatory Perspective on Analytical Method Validation During Product Development CASSS CMC Strategy Forum 2018 Jacek Cieslak CDER/OPQ/OBP FDA Disclaimer This presentation reflects the views of the author
More informationANTIBODY DRUG CONJUGATES AND BISPECIFIC ANTIBODIES: SCIENTIFIC & REGULATORY CHALLENGES AND OPPORTUNITIES
ANTIBODY DRUG CONJUGATES AND BISPECIFIC ANTIBODIES: SCIENTIFIC & REGULATORY CHALLENGES AND OPPORTUNITIES Brian DiPaolo 08 June 2017 CASSS Midwest Discussion Group Agenda Introduction Antibody Drug Conjugates
More informationSimilar biological medicinal product
SSPT, Tunis 13 November 2009 K. HO, Biological department - Biological medicinal product K. HO, Biological department Biological medicinal product Spectrum of complexity Spectrum of complexity Aspirin
More informationClinical qualification of specifications - a Regulator s view
Clinical qualification of specifications - a Regulator s view Mats Welin Medical Products Agency, Uppsala, Sweden Disclaimer: The opinions expressed are my own and do not necessarily represent those of
More informationGenetic Characterization of Production Cell Lines
Genetic Characterization of Production Cell Lines Luhong He and Christopher Frye 2017 CMC Strategy Forum Outlines Overview Genetic characterization strategy and case studies Transgene characterization
More informationCMC Strategy Forum Europe May Killarney, Ireland.
www.pei.de CMC Strategy Forum Europe 2015 22-24 May Killarney, Ireland. Technical innovations impact on regulatory expectations for product characterization Steffen Gross Head, Section Monoclonal and Polyclonal
More informationGuideline on the Requirements for Quality Documentation Concerning Biological Investigational Medicinal Products in Clinical Trials
1 2 3 18 February 2010 EMA/CHMP/BWP/534898/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the Requirements for Quality Documentation Concerning Biological Investigational
More informationA Regulatory Perspective on Characterization and Control of Process-Related Impurities
A Regulatory Perspective on Characterization and Control of Process-Related Impurities Christopher Downey, PhD FDA/CDER Office of Biotechnology Products CASSS Bay Area Discussion Group June 2017 Disclaimer
More informationKirsten L. Vadheim, Ph.D. BioCompliance Consulting, Inc. Presented at the ASBM Forum, February 25, 2014, Washington DC
Kirsten L. Vadheim, Ph.D. BioCompliance Consulting, Inc. Presented at the ASBM Forum, February 25, 2014, Washington DC klvadheim@hotmail.com The Importance of Data Over Time 2003: FDA approved innovator
More informationWork plan for the CHMP Biologics Working Party (BWP) 2011
15 September 2010 EMA/CHMP/BWP/360133/2010 Work plan for the CHMP Biologics Working Party (BWP) Chairperson: Jean-Hugues Trouvin 1. Meetings scheduled for 11-12 January 7-9 February 7-9 March 4-6 April
More informationGuideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics
Provisional Translation (as of April 19, 2013) PFSB/ELD Notification No. 0304007 March 4, 2009 To: Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food
More informationRegulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationRecent experience in scientific advice and marketing authorisations
Recent experience in scientific advice and marketing authorisations Presented by Brigitte Brake on 16 April 2015 BfArM & BWP, Germany An agency of the European Union Introduction Short introduction to
More informationWhat are the best ways to prepare antigen/antibody reagents with highest HCP coverage?
What are the best ways to prepare antigen/antibody reagents with highest HCP coverage? Regulators remained agnostic on technical approaches so long as the all of the HCP ELISA reagents are demonstrated
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE- GENERAL Health systems and products Medicinal products quality, safety and efficacy 18 February 2010 EMA/CHMP/BWP/534898/2008 Committee for Medicinal
More informationDivision of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
Reference No.: FDAA10017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 VIA WEB SUBJECT: Approval Pathway for Biosimilar and Interchangeable
More informationICH Q11 Development & manufacture of drug substances
ICH Q11 Development & manufacture of drug substances Keith McDonald Group Manager Medicines & Healthcare products Regulatory Agency (UK) 2011 ICH International Conference on Harmonisation of Technical
More informationSubject Index. chromatography step, 125-
A Alert limits, description, 70 Aluminum hydroxide based vaccine manufacture, start up and validation of sterile formulation and filling processes, 144-168 Anion-exchange chromatography step for clinical-grade
More informationNew proposal from the EC:
New proposal from the EC: Gene therapy medicinal product means a biological medicinal product which has the following characteristics: a. it contains an active substance which contains or consists of a
More informationSubject Index. See for options on how to legitimately share published articles.
Downloaded via 148.251.232.83 on March 27, 2019 at 03:59:27 (UTC). See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles. A Alert limits, description, 70
More informationCASSS CMC Strategy Forum Barcelona, Spain. EBE Satellite Session Comparability Concept Paper 21 st March 2011
CASSS CMC Strategy Forum Barcelona, Spain EBE Satellite Session Comparability Concept Paper 21 st March 2011 Aim of concept paper Points to consider in planning and undertaking of comparability exercise
More informationImmunogenicity. How to deal with? Nathalie Macé Sanofi, Biomarkers & Biological analyses Unit
Immunogenicity How to deal with? Nathalie Macé Sanofi, Biomarkers & Biological analyses Unit Club Phase I, 22 March 2016 1 Outline Introduction to immunogenicity Analytical challenges for immunogenicity
More informationNotice Our file number:
June 15, 2015 Notice Our file number: 15-107053-353 Adoption of ICH 1 Guidance: Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process Health Canada
More informationNDA Advisory Services Ltd
Declaration of Interest statement: Paul Chamberlain has received Consulting fees from different companies in respect of strategic and operational advice relating to biopharmaceutical development; he is
More informationWhat do physicians expect from a new drug?
What do physicians expect from a new drug? New drug Novel activity Efficacy Safety Affordable cost Approval of new biologic drugs Is consistently increasing New Biotech Drug and Vaccine Approvals/ New
More informationPHARMA KNOWLEDGE PARK
GUIDELINES 2013 WWW.NOORMD.COM A COMPILATION BY ON PHARMACEUTICAL REGULATORY GUIDELINES INTRODUCED / REVISED DURING THE YEAR 2013. Page 2 ICH Assessment and control of DNA reactive (mutagenic) impurities
More informationPreparing the CMC section of IMPD for biological/biotechnology derived substances
Preparing the CMC section of IMPD for biological/biotechnology derived substances Your Logo Dr. Una Moore Health Products Regulatory Authority, Ireland Presented by Una Moore on 16 th April 2014. Health
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationBHK Cell Host Cell Proteins
BHK Cell Host Cell Proteins Immunoenzymetric Assay for the Measurement of Baby Hamster Kidney (BHK) Host Cell Proteins Catalog # F510 Intended Use This kit is intended for use in determining the presence
More informationHarmonized Quality Requirements for Biotech Investigational Medicinal Products - A Regulator's View
Harmonized Quality Requirements for Biotech Investigational Medicinal Products - A Regulator's View Brigitte Brake Pharmaceutical Biotechnology BfArM, Bonn Evaluation Criteria National vs. EU Clinical
More informationQuality issues in biosimilars Some thoughts
Quality issues in biosimilars Some thoughts Norbert Benda Disclaimer: Views expressed in this presentation are the author's personal views and not necessarily the views of BfArM Statistical issues in quality
More informationReplacing Analytical Methods for Release and Stability Testing CBER Perspective
Replacing Analytical Methods for Release and Stability Testing CBER Perspective Presentation at the CMC Strategy Forum January 27, 2014 Lokesh Bhattacharyya Chief, Lab of Analytical Chemistry and Blood
More informationSubmission of comments on Guideline on Similar Biological Medicinal Products (CHMP/437/04 Rev1)
October 31, 2013 Submission of comments on Guideline on Similar Biological Medicinal Products (CHMP/437/04 Rev1) Comments from: Name of organisation or individual Biotechnology Industry Organization (BIO)
More informationExpectations for Bioassays - An Assessor s View
www.pei.de Expectations for Bioassays - An Assessor s View CASSS - Bioassays 2017 DoubleTree by Hilton Hotel Silver Spring, Maryland, USA Quality- and Non-clinical Assessor Section Mono- und Polyclonal
More informationConsiderations for Control Strategies for mab/mab Combination Therapies An Industry Perspective
Considerations for Control Strategies for mab/mab Combination Therapies An Industry Perspective Dieter Schmalzing, GBQC, South San Francisco Genentech, A Member of the Roche Group CMC Strategy Forum Europe
More informationVaccines based on Recombinant Proteins and Adjuvant Systems: GSK's malaria vaccine candidate as a case study.
Vaccines based on Recombinant Proteins and Adjuvant Systems: GSK's malaria vaccine candidate as a case study. CMC Forum Vienna May 25-27 Vaccine workshop M.-C. Uwamwezi, Senior scientist Regulatory Affairs,
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
1 2 3 23 June 2016 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the requirements for quality documentation concerning biological investigational
More informationDuring biopharmaceutical
B i op r o c e s s Technical Development of an In-House, Process-Specific ELISA for Detecting HCP in a Therapeutic Antibody, Part 2 Edward Savino, Bing Hu, Jason Sellers, Andrea Sobjak, Nathan ajewski,
More informationVendor Neutral Host Cell Protein Analysis
Vendor Neutral Host Cell Protein Analysis Regulator Positions on HCPs VERY CLEAR Regulators classify residual host cell proteins (HCPs) as process-related impurities [ICH Q6B, Q2B]. Finding, measuring
More informationHeLa Host Cell Proteins
HeLa Host Cell Proteins Immunoenzymetric Assay for the Measurement of HeLa Cell Host Cell Proteins Catalog # F810 Intended Use This kit is intended for use in determining the presence host cell protein
More informationA549 Cell Host Cell Proteins
A549 Cell Host Cell Proteins Immunoenzymetric Assay for the Measurement of A549 Host Cell Proteins Catalog # F230 Intended Use This kit is intended for use in determining the presence of protein contamination
More informationMedicines Agency EMA & Biosimilar update: Trends from marketing authorisation applications, scientific advice procedures and policies
EMA & Biosimilar update: Trends from marketing authorisation applications, scientific advice procedures and policies Presented by: Peter Richardson Head of Quality Office Specialised Scientific Disciplines
More informationVICH Topic GL40. at Step 7 GUIDELINE ON TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW BIOTECHNOLOGICAL/BIOLOGICAL VETERINARY MEDICINAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 15 November 2005 Doc. Ref. EMEA/CVMP/VICH/811/04- corrigendum 1 VICH Topic GL40 at Step 7 GUIDELINE ON TEST PROCEDURES AND ACCEPTANCE
More informationValidation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.
Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals. 1 Analytical Method Validation: 1..1 Philosophy: Method validation is
More informationCMC Strategy Forum, Paris 2008
Assay Validation Studies in Clinical Development: Regulatory Perspective CMC Strategy Forum, Paris 2008,, Germany 1 Scope Biologicals PEI Analytical Validation Not: Process Validation Investigational products
More informationVero Cell Host Cell Proteins
Vero Cell Host Cell Proteins Immunoenzymetric Assay for the Measurement of Vero Cell Host Cell Proteins Catalog # F500 Intended Use This kit is intended for use in determining the presence of host cell
More informationCHO Host Cell Proteins 3 rd Generation
CHO Host Cell Proteins 3 rd Generation Immunoenzymetric Assay for the Measurement of CHO Host Cell Proteins Catalog # F550 Intended Use This kit is intended for use in determining the presence of host
More informationPharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA
Pharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA 1 2 ND MENA Regulatory Conference On Bioequivalence, Biowaivers, Bioanalysis, Dissolution & Biosimilars
More informationCAP cell Host Cell Proteins
CAP cell Host Cell Proteins Immunoenzymetric Assay for the Measurement of CAP cell line Host Cell Proteins Catalog # F820 Intended Use This kit is intended for use in determining the presence of host cell
More informationCurrent Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues
Current Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues Dr. René Thürmer BfArM - and dmedical ldevices AGAH Workshop on Liposomal Formulations Bonn / 21.
More informationMethods to Determine the Binding of Bevacizumab to Fc receptors
DATASHEET Methods to Determine the Binding of Bevacizumab to Fc receptors BACKGROUND Bevacizumab (Avastin ) is a humanized recombinant monoclonal antibody that inhibits angiogenesis by binding to the vascular
More informationGuideline on setting specifications for related impurities in antibiotics
1 2 3 4 14 July 2010 EMA/CHMP/CVMP/QWP/199250/2009 Committee for Medicinal Products for Human Use (CHMP) / Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 7 Guideline on setting specifications
More informationFebruary 27, 2008 NOTICE. Consultation on Draft Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs)
February 27, 2008 NOTICE Consultation on Draft Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs) The above referenced draft guidance will be the topic
More informationComparability Is Not a Nightmare, Just Think Ahead!
Comparability Is Not a Nightmare, Just Think Ahead! Margarida Menezes Ferreira Senior Assessor at INFARMED PT expert at BWP/CHMP - EMA member of the CAT - EMA (margarida.menezes@infarmed.pt) I attend this
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
14 September 2017 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the requirements for quality documentation concerning biological investigational medicinal
More informationAPPLYING SCIENTIFIC CONSIDERATIONS AND STATISTICAL APPROACHES IN ANALYTICAL SIMILARITY ASSESSMENT
APPLYING SCIENTIFIC CONSIDERATIONS AND STATISTICAL APPROACHES IN ANALYTICAL SIMILARITY ASSESSMENT JENNIFER LIU CASSS CMC STRATEGY FORUM EUROPE 2017, MAY 22-24 BIOSIMILAR DEVELOPMENT BEGINS WITH THOROUGH
More informationBiomarker Regulation. Regulator s perspective. Jan Müller-Berghaus
www.pei.de Biomarker Regulation Regulator s perspective Jan Müller-Berghaus The views presented here are my own and do not necessarily reflect the views of the Paul-Ehrlich-Institut or any other regulatory
More informationSetting Specifications for Biotech Products
Setting Specifications for Biotech Products Session 1: What to Control? Presentation by an EU Regulator Nanna Aaby Kruse, Senior Biological Assessor, member of BWP and BMWP WHAT TO CONTROL? Control of
More informationSaccharomyces cerevisiae Host Cell Proteins
Saccharomyces cerevisiae Host Cell Proteins Immunoenzymetric Assay for the Measurement of Saccharomyces cerevisiae Host Cell Proteins Catalog # F135 Intended Use This kit is intended for use in determining
More informationFDA recommendations for comparability studies to support manufacturing changes. Joslyn Brunelle, PhD Office of Biotechnology Products OPQ/CDER/FDA
FDA recommendations for comparability studies to support manufacturing changes Joslyn Brunelle, PhD Office of Biotechnology Products OPQ/CDER/FDA The views and opinions expressed here should not be used
More informationThe European Approach on Large Sample Sizes in the context of a PAT Environment
The European Approach on Large Sample Sizes in the context of a PAT Environment Dr. Michael Wierer, Deputy Head, European Pharmacopoeia Department, European Directorate for the Quality of Medicines & HealthCare
More informationSP 2/0 Host Cell Proteins
SP 2/0 Host Cell Proteins Immunoenzymetric Assay for the Measurement of SP 2/0 Host Cell Proteins Catalog # F180 Intended Use This kit is intended for use in determining the presence of SP 2/0 host cell
More informationImplementation of the ICH Q3D guideline in the Ph. Eur.
Implementation of the ICH Q3D guideline in the Ph. Eur. PQRI/USP Workshop, USP Meeting center 9-10 November 2016 Bruno Spieldenner, Ph. Eur. division, EDQM Elemental impurities in the Ph. Eur. A (r)evolution
More informationCHALLENGES AND SOLUTIONS TO RECEPTOR OCCUPANCY STUDIES BY FLOW CYTOMETRY
CHALLENGES AND SOLUTIONS TO RECEPTOR OCCUPANCY STUDIES BY FLOW CYTOMETRY 4th RSC / DMDG / DMG New Perspectives in DMPK James Munday Science Lead I&I (Harrogate, UK) 21 st -22nd May 2018 Copyright 2018
More information3D Structure of Biologics in a Convenient Immunoassay Format
3D Structure of Biologics in a Convenient Immunoassay Format Xing Wang, Ph.D. Array Bridge Inc. 5/25/2017 1 Topics Covered Today Why New Technologies? Technology Development. Case Studies for Novel and
More informationOptimization of 2D Gel Transblotting for Host Cell Protein Analysis
Optimization of 2D Gel Transblotting for Host Cell Protein Analysis Jon Johansen, Matt Hoelter & Nancy Kendrick* Kendrick Labs Inc, Madison, WI www.kendricklabs.com Talk Outline Biologic drugs, recombinant
More informationChinese Hamster Ovary Host Cell Proteins
Chinese Hamster Ovary Host Cell Proteins Immunoenzymetric Assay for the Measurement of Chinese Hamster Ovary Host Cell Proteins Catalog # F015 Intended Use This kit is intended for use in determining the
More informationGuideline on good pharmacovigilance practices (GVP)
4 August 2016 EMA/168402/2014 Corr* Guideline on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations II: Biological medicinal products Draft finalised by the Agency in
More informationGuidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs
9 November 2017 EMA/CHMP/CVMP/3Rs/94436/2014 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) Guidance for individual laboratories for transfer
More informationHEK 293 Host Cell Proteins 2 nd Generation
HEK 293 Host Cell Proteins 2 nd Generation Immunoenzymetric Assay for the Measurement of HEK 293 Host Cell Proteins Catalog # F650 Intended Use This kit is intended for use in determining the presence
More informationComments and suggestions from reviewer
Comments and suggestions from reviewer Page 1 of 13 Title: WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology: WHO/rDNA_DRAFT/12
More informationBHK Cell Host Cell Proteins
BHK Cell Host Cell Proteins Immunoenzymetric Assay for the Measurement of Baby Hamster Kidney (BHK) Host Cell Proteins Catalog # F510 Intended Use This kit is intended for use in determining the presence
More informationProcess Analytical Technologies View Point of the Regulators
Process Analytical Technologies View Point of the Regulators Jean-Louis ROBERT, Ph.D. Chair QWP Laboratoire National de Santé Luxembourg Cannes, 3 May 2004 1 Process analytical Technologies This presentation
More informationArchived Content. This content was archived on June 24, 2013.
This content was archived on June 24, 2013. Archived Content Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after
More informationPER.C6 cells Host Cell Proteins
PER.C6 cells Host Cell Proteins Immunoenzymetric Assay for the Measurement of PER.C6 cell line Host Cell Proteins Catalog # F530 Intended Use This kit is intended for use in determining the presence of
More informationSharmila et al. International Journal of Drug Regulatory Affairs; 2017, 5(1), ISSN: Available online at
REGULATORY REQUIREMENTS OF SIMILAR BIOLOGICS FOR MARKETING AUTHORIZATION IN INDIA Available online at www.ijdra.com REVIEW ARTICLE Sharmila Reddy V*, Mounica N.V.N., Anusha S, Evangeline L, Nagabhushanam
More informationImpurities from degradation of Drug Substances
Impurities from degradation of Drug Substances REFERENCE 1. ICH - IMPURITIES IN NEW DRUG SUBSTANCES - Q3A(R2) 2. ICH - IMPURITIES IN NEW DRUG PRODUCTS - Q3B(R2) 3. ICH - VALIDATION OF ANALYTICAL PROCEDURES:
More informationQuality, Safety and Efficacy of Follow-on Biologics
Quality, Safety and Efficacy of Follow-on Biologics Teruhide YAMAGUCHI Division of Biological Chemistry and Biologicals National Institute of Health Sciences 2009.9.28 London Quality, Safety and Efficacy
More informationCharacterization of Biotechnology Products: A Regulatory Perspective
Characterization of Biotechnology Products: A Regulatory Perspective Laurie Graham Acting Team Leader FDA/CDER/OPS/OBP Division of Monoclonal Antibodies WCBP 2013 1 Disclaimer The views and opinions expressed
More informationExpectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective
Expectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective Christian Mayer AGES - Austrian Agency for Health and Food Safety Analytical Technologies Europe
More informationHEK 293 Host Cell Proteins
HEK 293 Host Cell Proteins Immunoenzymetric Assay for the Measurement of HEK 293 Host Cell Proteins Catalog # F650R Intended Use This kit is intended for use in determining the presence host cell protein
More information